Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) Enterprise Value (2016 - 2026)

Ekso Bionics Holdings has reported Enterprise Value over the past 14 years, most recently at -$2.7 million for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 67.17% to -$2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.7 million, a 67.17% increase, with the full-year FY2024 number at -$2.0 million, up 76.85% from a year prior.
  • Enterprise Value reached -$2.7 million in Q3 2025 per EKSO's latest filing, up from -$5.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$2.0 million in Q4 2024, with the low at -$49.5 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$13.3 million (2023), against an average of -$20.3 million.
  • Peak YoY movement for Enterprise Value: plummeted 481.72% in 2021, then surged 76.85% in 2024.
  • Tracing EKSO's Enterprise Value over 5 years: stood at -$40.4 million in 2021, then skyrocketed by 49.2% to -$20.5 million in 2022, then soared by 57.91% to -$8.6 million in 2023, then surged by 76.85% to -$2.0 million in 2024, then tumbled by 36.1% to -$2.7 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$2.7 million, -$5.2 million, and -$8.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.